<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098346</article-id><article-id pub-id-type="publisher-id">1592012</article-id><article-id pub-id-type="doi">10.3389/fphar.2025.1592012</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Loss of expression and function of G&#x003b2;&#x003b3; by GNB1 encephalopathy-associated L95P mutation of the G&#x003b2;<sub>1</sub> subunit</article-title><alt-title alt-title-type="left-running-head">Reddy et al.</alt-title><alt-title alt-title-type="right-running-head">
<ext-link xlink:href="https://doi.org/10.3389/fphar.2025.1592012" ext-link-type="uri">10.3389/fphar.2025.1592012</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Reddy</surname><given-names>Haritha P.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/2226895/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author"><name><surname>Keren-Raifman</surname><given-names>Tal</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author"><name><surname>Tabak</surname><given-names>Galit</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author"><name><surname>Dascal</surname><given-names>Nathan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/752169/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yakubovich</surname><given-names>Daniel</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/752297/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>School of Medicine</institution>, <institution>Tel-Aviv University</institution>, <addr-line>Tel Aviv</addr-line>, <country>Israel</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Sagol School of Neuroscience</institution>, <institution>Tel-Aviv University</institution>, <addr-line>Tel Aviv</addr-line>, <country>Israel</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>The Adelson School of Medicine</institution>, <institution>Ariel University</institution>, <addr-line>Ariel</addr-line>, <country>Israel</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Neonatology Department</institution>, <institution>Laniado Hospital</institution>, <addr-line>Netanya</addr-line>, <country>Israel</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/199231/overview" ext-link-type="uri">Petra Scholze</ext-link>, Medical University of Vienna, Austria</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/1310092/overview" ext-link-type="uri">Jacy Wagnon</ext-link>, The Ohio State University, United States</p><p>
<ext-link xlink:href="https://loop.frontiersin.org/people/301210/overview" ext-link-type="uri">Armando Alberola-Die</ext-link>, University of Alicante, Spain</p></fn><corresp id="c001">*Correspondence: Daniel Yakubovich, <email>danielya@ariel.ac.il</email>; Haritha P. Reddy, <email>haritha89reddy@gmail.com</email>
</corresp><fn fn-type="present-address" id="fn1"><label>
<sup>&#x02020;</sup>
</label><p>
<bold>Present address:</bold> Haritha P. Reddy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark</p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1592012</elocation-id><history><date date-type="received"><day>11</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Reddy, Keren-Raifman, Tabak, Dascal and Yakubovich.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Reddy, Keren-Raifman, Tabak, Dascal and Yakubovich</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Background</title><p>G-proteins areindispensable regulators of cellular signaling, with G-protein-gated inwardly rectifying potassium channels (GIRK) as key effectors. <italic>GNB1</italic> encephalopathy (GNB1E) is a congenital neurological syndrome resulting from mutations in the GNB1 gene, encoding the G&#x003b2;<sub>1</sub> subunit of G-proteins trimer (G&#x003b1;&#x003b2;&#x003b3;). GNB1E manifests as a global developmental delay, accompanied by tonus disturbances, ataxia, and epilepsy.</p></sec><sec><title>Methods</title><p>We utilized the <italic>Xenopus laevis</italic> oocyte heterologous expression system to investigate the impact of the L95P mutation in G&#x003b2;<sub>1</sub> (G&#x003b2;<sub>1</sub>-L95P) on the activation of neuronal GIRK channels GIRK2 and GIRK1/2. Mutant and wild-type (WT) G&#x003b2;<sub>1</sub> RNAs were co-injected with RNAs encoding the G&#x003b3;<sub>2</sub> and GIRK channel subunits. The expression levels of both G&#x003b2;<sub>1</sub> and the channel proteins, as well as the channel activity, were systematically monitored. Additionally, rigid-body docking was used to model the GIRK1/2&#x02013;G&#x003b2;&#x003b3; complex, evaluating L95P&#x02019;s effect on channel&#x02013;G&#x003b2;&#x003b3; interaction, G&#x003b2;&#x003b3; stability, and G&#x003b2;&#x003b3;&#x02013;effector affinity.</p></sec><sec><title>Results</title><p>. G&#x003b2;<sub>1</sub>-L95P exhibited reduced protein expression compared to WT. Even after RNA adjustments to restore comparable membrane localization, the mutant failed to effectively activate GIRK2 and GIRK1/2. Structural analysis revealed that L95 was not consistent in the G&#x003b2;&#x003b3;&#x02013;effector interface. Thermodynamic calculations suggested that the mutation primarily destabilized G&#x003b2;<sub>1</sub> and G&#x003b2;<sub>1</sub>&#x02013;effector complex.</p></sec><sec><title>Conclusion</title><p>G&#x003b2;<sub>1</sub>-L95P leads to both reduced protein expression and impaired function in the GIRK&#x02013;G&#x003b2;&#x003b3; interaction system. The later effect can be attributed to the changes associated with protein misfolding.</p></sec></abstract><kwd-group><kwd>GIRK channels</kwd><kwd>GNB1</kwd><kwd>mutation</kwd><kwd>modeling</kwd><kwd>docking</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the Israel Science Foundation (ISF), grant # 581/22 (ND).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Neuropharmacology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Heterotrimeric G-proteins (composed of G&#x003b1;, G&#x003b2;, and G&#x003b3; subunits) and G-protein-coupled receptors (GPCRs) constitute integral components of GPCR signaling (<xref rid="B35" ref-type="bibr">Pierce et al., 2002</xref>). G-proteins interact with the effectors, including ion channels, enzymes, and various other regulatory proteins, and they play a significant role in diverse physiological processes such as neurotransmission, cardiovascular regulation, endocrine system, metabolism, immune response, cell growth and differentiation, and other intricate intracellular communication pathways (<xref rid="B33" ref-type="bibr">Oldham and Hamm, 2008</xref>). G&#x003b2;&#x003b3; subunit dimers, or G&#x003b2;&#x003b3; subunits for simplicity, in particular, are involved in the activation of GIRK channels (G-protein-activated inwardly rectifying potassium channel), among other functions (<xref rid="B28" ref-type="bibr">Logothetis et al., 1987</xref>). Upon activation, these channels induce hyperpolarization of the plasma membrane in cardiac cells and neurons. This activation is crucial for mediating the inhibitory effects of various neurotransmitters, including GABA (<italic>via</italic> GABA-B receptors), acetylcholine (<italic>via</italic> M2 muscarinic receptors), opioids (<italic>via</italic> opioid receptors), and others. The modulation of GIRK channels by G&#x003b2;&#x003b3; subunits represents a key mechanism in the regulation of neuronal excitability and the intricate balance of neurotransmission in the central nervous system (<xref rid="B6" ref-type="bibr">Campos-Rios et al., 2022</xref>; <xref rid="B8" ref-type="bibr">Cui et al., 2021</xref>; <xref rid="B30" ref-type="bibr">Luo et al., 2022</xref>).</p><p>Over the past decade, a cohort of patients harboring mutations in the G&#x003b2;<sub>1</sub> subunit was described (<xref rid="B34" ref-type="bibr">Petrovski et al., 2016</xref>; <xref rid="B2" ref-type="bibr">Bassan et al., 2018</xref>). This group, identified with early-onset epilepsy, has been termed GNB1 encephalopathy (GNB1-E). Notable characteristics of these patients encompass developmental delay (DD) or intellectual disability (ID), frequently observed infantile hypotonia progressing to hypertonia, and structural brain abnormalities, accompanied by a spectrum of seizure types such as tonic, absence, myoclonic, generalized tonic-clonic, and focal seizures, along with epileptic spasms. Importantly, <italic>GNB1</italic> has emerged as a potential candidate gene associated with West syndrome, and several individuals with <italic>GNB1</italic>-E have had West syndrome or infantile spasms (<xref rid="B10" ref-type="bibr">Da Silva et al., 2021</xref>; <xref rid="B11" ref-type="bibr">Endo et al., 2020</xref>; <xref rid="B16" ref-type="bibr">Hemati et al., 2018a</xref>; <xref rid="B20" ref-type="bibr">Jones et al., 2019</xref>; <xref rid="B42" ref-type="bibr">Schultz-Rogers et al., 2020</xref>; <xref rid="B38" ref-type="bibr">Revah-Politi et al., 2020</xref>).</p><p>GNB1-E is an autosomal dominant rare genetic disorder, with approximately 70 documented cases worldwide. The reported mutations associated with GNB1-E consist of 36 variants affecting 25 residues (<xref rid="B38" ref-type="bibr">Revah-Politi et al., 2020</xref>; <xref rid="B26" ref-type="bibr">Lansdon and Saunders, 2021</xref>). This suggests the existence of mutational hotspots, where certain amino acid positions are particularly susceptible to genetic alterations associated with GNB1-E. The most prevalent mutation, I80T, has been identified in at least 17 patients (<xref rid="B11" ref-type="bibr">Endo et al., 2020</xref>; <xref rid="B49" ref-type="bibr">Tsuji et al., 2023</xref>; <xref rid="B17" ref-type="bibr">Hemati et al., 2018b</xref>). Our prior investigations extensively examined the I80T, I80N, and K78R mutations using the <italic>Xenopus laevis</italic> oocyte heterologous expression system. We found that the K78R mutation exhibits a gain of expression alongside a partial loss of function when interacting with GIRK1/2, whereas I80T and I80N mutations are characterized by a partial loss of expression with a concurrent loss of function in GIRK2 activation (<xref rid="B37" ref-type="bibr">Reddy et al., 2021</xref>).</p><p>Moreover, we extended our studies to a mouse model harboring the K78R mutation, demonstrating a recapitulation of developmental delay and epileptic features observed in human cases. Notably, ethosuximide, a potent GIRK inhibitor, was found to suppress spike-wave discharges (SWDs) <italic>in vivo</italic> and restore normal network behavior <italic>in vitro</italic>, highlighting potential therapeutic avenues for managing GNB1-E-associated symptoms (<xref rid="B7" ref-type="bibr">Colombo et al., 2023</xref>; <xref rid="B43" ref-type="bibr">Shalomov et al., 2025</xref>).</p><p>In light of our previous findings, we continued to study the impact of GNB1 mutants on GIRK channels&#x02019; activity and expressions in <italic>Xenopus laevis</italic> oocytes. In the current work, we characterized the GIRK1/2 and GIRK2 structural&#x02013;functional relationship with L95P mutation of G&#x003b2;<sub>1</sub>, G&#x003b2;<sub>1</sub>-L95P (c.284T &#x0003e; C in exon 7). As of now, L95P is the second most prevalent mutation (seven documented cases: five female, one male, and one unknown) among the GNB1-E patients after I80T (<xref rid="B11" ref-type="bibr">Endo et al., 2020</xref>; <xref rid="B26" ref-type="bibr">Lansdon and Saunders, 2021</xref>; <xref rid="B49" ref-type="bibr">Tsuji et al., 2023</xref>; <xref rid="B17" ref-type="bibr">Hemati et al., 2018b</xref>). L95P is strongly associated with cleft palate compared to other GNB1 mutations. L95P is also associated with developmental delay and seizures (<xref rid="B34" ref-type="bibr">Petrovski et al., 2016</xref>; <xref rid="B11" ref-type="bibr">Endo et al., 2020</xref>; <xref rid="B16" ref-type="bibr">Hemati et al., 2018a</xref>). Here, we report that L95P mutation is associated with combined loss of expression and loss of function of GNB1.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and methods</title><sec id="s2-1"><title>
<italic>Xenopus laevis</italic> frog maintenance and oocyte collection</title><p>The experiments were authorized by and conducted in accordance with the guidelines provided by the Tel Aviv University Institutional Animal Care and Use Committee under permits #01-16-104 and 01-20-083. Female <italic>Xenopus laevis</italic> frogs were cared for and subjected to procedures such as oocyte defolliculation, incubation, and RNA injection, following established protocols (<xref rid="B9" ref-type="bibr">Dascal and Lotan, 1992</xref>). The frogs were housed in tanks with dechlorinated water and maintained under a 10-h light/14-h dark cycle at 19&#x000b0;C &#x000b1; 2&#x000b0;C. Ovary portions were extracted through a small incision in the abdomen under anesthesia (0.2%&#x02013;0.25% solution of tricaine methanesulphonate). Following suturing, frogs were placed in a separate tank to recover from anesthesia before being transferred to a postoperative animals&#x02019; tank. The frogs exhibited no signs of postoperative distress and were allowed a recovery period of at least 3&#x000a0;months. After three to four surgeries, anaesthetized frogs were humanely euthanized through decapitation and double pithing.</p><p>Oocytes underwent defolliculation using collagenase (type 1A, Sigma) in a Ca-free ND96 solution (see below). Following a 2&#x02013;4&#x000a0;h shaking incubation at room temperature, the oocytes were washed and transferred to a Petri dish with fresh ND96 solution and placed in an incubator at 20&#x000b0;C overnight. The subsequent day, visually healthy oocytes were sorted into a fresh dish and maintained in the incubator using NDE solution (ND96 supplemented with 2.5&#x000a0;mM pyruvate and 50&#x000a0;&#x003bc;g/mL gentamicin) at 20&#x000b0;C until RNA injection or further utilization, with daily solution changes. RNA injection followed established procedures (<xref rid="B41" ref-type="bibr">Rubinstein et al., 2009</xref>), involving the injection of 50&#x000a0;nL of RNA into healthy oocytes, which were then incubated for 2&#x02013;4 days in NDE solution. The standard ND96 solution, with a pH of 7.6&#x02013;7.8, comprised 96&#x000a0;mM NaCl, 2&#x000a0;mM KCl, 1&#x000a0;mM MgCl<sub>2</sub>, 1&#x000a0;mM CaCl<sub>2</sub>, and 5&#x000a0;mM HEPES, with NaOH titration. CaCl<sub>2</sub> was excluded in Ca<sup>2+</sup>-free ND96.</p></sec><sec id="s2-2"><title>DNA constructs and RNA</title><p>The DNA constructs utilized for experiments in <italic>Xenopus</italic> oocytes were inserted into high-expression oocyte vectors pGEM-HE or pGEM-HJ, following previously established methods (<xref rid="B5" ref-type="bibr">Berlin et al., 2011</xref>; <xref rid="B40" ref-type="bibr">Rishal et al., 2005</xref>). Most DNA constructs were reported earlier, including bovine G&#x003b2;<sub>1</sub>, bovine G&#x003b3;<sub>2</sub>, rat GIRK1, mouse GIRK2, YFP-GIRK1 (rat), and mouse GIRK2-YFP (<xref rid="B54" ref-type="bibr">Yakubovich et al., 2015</xref>; <xref rid="B45" ref-type="bibr">Tabak et al., 2019</xref>). The G&#x003b2;<sub>1</sub>L95P point mutation was introduced to bovine G&#x003b2;<sub>1</sub> through PCR-site directed mutagenesis using standard procedures with the PWO master PCR kit (Roche # 03789403001). DNA preparation employed the Wizard<sup>&#x000ae;</sup> Plus SV Miniprep kit (Promega # A1460). RNA synthesis followed established protocols (<xref rid="B39" ref-type="bibr">Rishal et al., 2003</xref>), with the amounts of injected RNA specified in the text and figure legends.</p></sec><sec id="s2-3"><title>Giant membrane patches (GMPs)</title><p>Giant membrane patches from oocyte membranes were prepared and visualized following established procedures (<xref rid="B44" ref-type="bibr">Singer-Lahat et al., 2000</xref>; <xref rid="B21" ref-type="bibr">Kahanovitch et al., 2014</xref>). Oocytes were manually devitellinized using fine forceps in a hypertonic solution (containing in mM: NaCl 56, KCl 150, MgCl<sub>2</sub> 4, and HEPES 10; pH 7.6). The devitellinized oocytes were placed on a Thermanox&#x02122; coverslip (Nunc, Roskilde, Denmark) submerged in a Ca<sup>2+</sup>-free ND96 solution, with their animal pole facing the coverslip, for 10&#x02013;20&#x000a0;min. Suctioning with a Pasteur pipette was then performed, resulting in a giant plasma membrane patch attached to the coverslip, with the cytosolic face oriented toward the external medium. The coverslip was thoroughly rinsed with fresh ND96 solution and fixed using 4% formaldehyde for 30&#x000a0;min. Fixed giant plasma membrane patches underwent immunostaining in 5% milk in phosphate buffer solution (PBS). Nonspecific binding was blocked with donkey IgG at a 1:200 ratio (Jackson ImmunoResearch, West Grove, PA, United States). Rabbit anti-G&#x003b2;<sub>1</sub> antibody (Abcam, ab 137635) was applied at a 1:300 dilution for 45&#x000a0;min at 37&#x000b0;C. Subsequently, a DyLight 650-labeled secondary antibody (Goat Anti-rabbit IgG, 1:200; Abcam, ab 96886) was applied for 30&#x000a0;min at 37&#x000b0;C, followed by PBS washing and mounting on a slide for visualization. Immunostained slides were stored at 4&#x000b0;C for no longer than a week.</p></sec><sec id="s2-4"><title>Confocal imaging</title><p>Confocal imaging was conducted using Zeiss LSM 710 or Leica TCS SP8 confocal microscopes equipped with a &#x000d7;20 objective. For whole oocytes, the image was focused on the animal (dark) hemisphere at the equator. YFP was excited with the 514&#x000a0;nm line of the argon laser, and emission was collected at 535&#x02013;546&#x000a0;nm. Fiji, an ImageJ-based software (<ext-link xlink:href="https://imagej.net/ij/" ext-link-type="uri">https://imagej.net/ij/</ext-link>), was employed for image analysis. Fluorescent signals were averaged from three regions of interest (ROIs) at the plasma membrane (PM) and three similar ROIs from the coverslip outside the oocyte&#x02019;s image. The average background signal was subtracted from the average PM signal in each oocyte, followed by subtracting the average net signal from the membrane of uninjected (na&#x000ef;ve) oocytes.</p><p>For confocal imaging of proteins in giant plasma membrane patches (GMPs), DyLight 650 was excited using a 633&#x000a0;nm laser, and emission was collected at 663&#x02013;673&#x000a0;nm. Images were centered on the edges of the membrane patches to observe and subtract background fluorescence from the coverslip. Fiji software (<ext-link xlink:href="https://imagej.net/software/fiji/" ext-link-type="uri">https://imagej.net/software/fiji/</ext-link>) was used for image analysis, selecting two ROIs: one covering most of the membrane patch within the field of view and another comprising background fluorescence, which was subtracted from the signal obtained from the patch. The average signal from giant plasma membrane patches of native oocytes&#x02019; membranes in the same experiment, immunostained using the same protocol, was subtracted from all groups.</p></sec><sec id="s2-5"><title>Two electrode voltage clamp (TEVC)</title><p>All experiments were conducted within a temperature range of 20&#x000b0;C&#x02013;22&#x000b0;C, following procedures outlined in a prior work (<xref rid="B41" ref-type="bibr">Rubinstein et al., 2009</xref>). Currents were recorded at &#x02212;80&#x000a0;mV, filtered at 20&#x000a0;Hz, and sampled at rates of 5 or 10&#x000a0;kHz. Whole-cell GIRK currents in oocytes were assessed using two-electrode voltage clamp (TEVC) with GeneClamp 500 (Molecular Devices, Sunnyvale, CA, United States) utilizing agarose cushion electrodes filled with 3M KCl, featuring resistances of 0.1&#x02013;0.8&#x000a0;M&#x003a9; for the current electrode and 0.2&#x02013;1.5&#x000a0;M&#x003a9; for the voltage electrode.</p><p>For measuring GIRK currents through direct activation by G&#x003b2;&#x003b3;, oocytes were injected with RNAs of GIRK1 and GIRK2 (0.05&#x000a0;ng) or GIRK2 (2&#x000a0;ng) or YFP-GIRK1 and GIRK2 (0.5&#x000a0;ng) or GIRK2-YFP (2&#x000a0;ng), along with the specified amounts of G&#x003b2;<sub>1</sub> RNA. The G&#x003b3;<sub>2</sub> RNA amount was maintained at 1/5 of G&#x003b2; to achieve roughly equal molar ratios of G&#x003b2; and G&#x003b3; RNAs. GIRK channel currents were measured in ND96 (2&#x000a0;mM&#x000a0;K or LK) solution or high-K<sup>+</sup> solution (HK24), featuring the following composition in mM: 24 KCl, 72 NaCl, 1 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, and 5 HEPES. The pH of all solutions ranged from 7.4 to 7.6. The recording protocol is shown in <xref rid="s11" ref-type="sec">Supplementary Figure S1</xref>.</p></sec><sec id="s2-6"><title>Quantification and statistical analysis</title><p>Statistical analyses were carried out using GraphPad Prism version 10 for Windows (GraphPad Software, La Jolla, California United States). Two-group comparisons employed the t-test when the data passed both the Shapiro&#x02013;Wilk normality test and the equal variance test; otherwise, the Mann&#x02013;Whitney rank sum test was utilized. Multiple group comparisons were conducted using one-way ANOVA (ANOVA on ranks when data did not follow a normal distribution). Tukey&#x02019;s test was applied for normally distributed data, whereas the Kruskal&#x02013;Wallis test was used otherwise.</p><p>The data in the graphs are presented as mean &#x000b1; SEM. Statistical differences are indicated as follows: asterisks (&#x02217;) denote comparisons between channels with WT G&#x003b2; and mutant groups; the octothorpe sign (#) indicates comparisons with the channel alone (no G&#x003b2;&#x003b3;) group and G&#x003b2;&#x003b3; groups. Significance levels are represented as follows: &#x02217; or #, p &#x0003c; 0.05; &#x02217;&#x02217; or ##, p &#x0003c; 0.01; &#x02217;&#x02217;&#x02217; or ###, p &#x0003c; 0.001; &#x02217;&#x02217;&#x02217;&#x02217; or ####, p &#x0003c; 0.0001.</p></sec><sec id="s2-7"><title>Structural analysis of G&#x003b2;&#x003b3;&#x02013;effector interaction</title><sec id="s2-7-1"><title>Interface and thermodynamic analysis</title><p>PDB files were analyzed in PRODIGY (<xref rid="B53" ref-type="bibr">Xue et al., 2016</xref>), and lists of amino acids located in the interface between two protein molecules (i.e., G&#x003b2;&#x003b3; and channel or other effector) were created. Interface amino acids data are defined by the PRODIGY server as residues in two protein molecules at 5.5 &#x0212b; and below distance from each other. In order to predict a possible role of L95P mutation in the stability of G&#x003b2; subunit and its influence on protein&#x02013;protein interactions in G&#x003b2;&#x003b3;&#x02013;effector complexes, structural models were submitted to the MCSM server (<xref rid="B36" ref-type="bibr">Pires et al., 2014</xref>). The change in protein stability or in the affinity of the protein&#x02013;protein interaction was defined as significant in case &#x00394;&#x00394;G was larger than 1&#x000a0;kcal/mol, which corresponds to &#x0223c;5 fold change in dissociation constant at 25&#x000b0;C (<xref rid="B4" ref-type="bibr">Berg et al., 2012</xref>) (&#x0223c;0.6&#x000a0;kcal/mol is considered the noise threshold (<xref rid="B23" ref-type="bibr">Kessel and Ben-Tal, 2018</xref>)).</p></sec></sec><sec id="s2-8"><title>G&#x003b2;&#x003b3; docking procedure</title><p>For docking, we utilized the G&#x003b2;&#x003b3; structure from the crystal structure of GIRK2/G&#x003b2;&#x003b3; complex [4KFM (<xref rid="B52" ref-type="bibr">Whorton and MacKinnon, 2013</xref>)], separated from the channel, and a tentative structure of GIRK1/2 heterotetramer described by Gazgalis et al. generated based on homology modeling (<xref rid="B13" ref-type="bibr">Gazgalis et al., 2022</xref>). For G&#x003b2;&#x003b3; docking, we utilized the rigid body docking algorithm implemented at the ClusPro 2.0 server (<xref rid="B25" ref-type="bibr">Kozakov et al., 2017</xref>). No space limitations were imposed during the docking procedure. As a result of the docking procedure, 120 clusters of possible GIRK1/2&#x02013;G&#x003b2;&#x003b3; models were generated and segregated according to balanced, hydrophobic favorite, electrostatic favorite, and van der Waals favorite energy scores. The corresponding centroid models of all clusters were further analyzed utilizing a method similar to that described by <xref rid="B31" ref-type="bibr">Mahajan et al. (2013)</xref>. In particular, we generated a GIRK1/2 membrane-embedded structure utilizing OPMM (<xref rid="B29" ref-type="bibr">Lomize et al., 2012</xref>) and aligned each of the docking models with this structure. Consequently, all models in which any G&#x003b2;&#x003b3; atom was located above the lower membrane leaflet and all models in which the C-terminal &#x003b1;-carbon of G&#x003b3; was more than 30&#x000c5; from the lower membrane leaflet were excluded from further analysis. These criteria assured that G&#x003b2;&#x003b3; structures implemented for further analysis would be sufficiently close to the plasma membrane, as expected from geranylgeranyl modification of G&#x003b3; C-terminus (<xref rid="B18" ref-type="bibr">Hibino et al., 2010</xref>).</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3-1"><title>L95P mutation leads to a partial loss of expression of G&#x003b2;<sub>1</sub> protein</title><p>In this study, groups of oocytes were injected with varying amounts of either WT G&#x003b2;<sub>1</sub> or G&#x003b2;<sub>1</sub>-L95P mRNA, together with G&#x003b3; and channel mRNA (GIRK2 or GIRK1/2). The levels of G&#x003b2; expression in the plasma membrane were quantified using the giant membrane patch methodology, which allows to visualize and monitor plasma membrane-attached G&#x003b2;&#x003b3; with a G&#x003b2; antibody. Concurrently, oocytes from the same RNA injection groups were employed for electrophysiological experiments. Representative pictures obtained from confocal imaging for G&#x003b2;<sub>1</sub>-L95P and WT G&#x003b2; expressed with GIRK2 and GIRK1/2 channels, respectively, are shown in <xref rid="F1" ref-type="fig">Figures 1A</xref>, <xref rid="F2" ref-type="fig">2A</xref>. Notably, regardless of which channel was co-expressed with the G&#x003b2;&#x003b3; under investigation, the mutant G&#x003b2;&#x003b3; consistently exhibited lower expression levels, as illustrated in <xref rid="F1" ref-type="fig">Figures 1B</xref>, <xref rid="F2" ref-type="fig">2B</xref>. Using higher amounts of injected G&#x003b2;<sub>1</sub>-L95P RNA, we could attain levels of expression comparable to the levels of WT G&#x003b2; obtained with lower doses of RNA, both in GIRK2 and GIRK1/2 channel-expressing oocytes (<xref rid="F1" ref-type="fig">Figures 1B</xref>, <xref rid="F2" ref-type="fig">2B</xref>). This result suggests a partial loss of G&#x003b2;<sub>1</sub> protein expression, indicating either reduced synthesis of G&#x003b2;<sub>1</sub>-L95P or an increased rate of its degradation, or a combination of both.</p><fig position="float" id="F1"><label>FIGURE 1</label><caption><p>
<bold>(A)</bold> Representative images of membrane patches at G&#x003b2; RNA doses 1 and 5&#x000a0;ng for G&#x003b2;WT and 1, 5, and 10&#x000a0;ng for G&#x003b2;L95P in the presence of GIRK2 channels. Plasma membrane patches were stained with an antibody against G&#x003b2;<sub>1</sub>. Membranes are seen as brighter-colored areas, and the background is black. (<italic>PM</italic>, plasma membrane; <italic>bckd</italic>, background). Number of frog donors (N) = 1. <bold>(B)</bold> Surface expression of G&#x003b2;WT and G&#x003b2;L95P mutant in the presence of GIRK2, measured in GMP. Data shown are the mean fluorescence intensity produced by the expressed G&#x003b2;, after subtraction of the average signal observed in channel-alone oocytes. (GMP, giant membrane patches). Statistical analysis: one-way ANOVA ####p &#x0003c; 0.0001, ###p &#x0003c; 0.001, ##p &#x0003c; 0.01, and #p &#x0003c; 0.05 relative to channel-only group and ****p &#x0003c; 0.0001, ***p &#x0003c; 0.001, **p &#x0003c; 0.01, and *p &#x0003c; 0.05 relative to G&#x003b2;WT. <bold>(C)</bold> Representative current traces of GIRK2 channels. <bold>(D)</bold> Summary of GIRK2 activation by G&#x003b2;WT and G&#x003b2;L95P. Statistical analysis: one-way ANOVA ####p &#x0003c; 0.0001, ###p &#x0003c; 0.001, ##p &#x0003c; 0.01, and #p &#x0003c; 0.05 relative to channel-only group and ****p &#x0003c; 0.0001, ***p &#x0003c; 0.001, **p &#x0003c; 0.01, and *p &#x0003c; 0.05 relative to G&#x003b2;WT.</p></caption><graphic xlink:href="fphar-16-1592012-g001" position="float"/></fig><fig position="float" id="F2"><label>FIGURE 2</label><caption><p>
<bold>(A)</bold> Representative images of membrane patches at G&#x003b2; RNA doses 1 and 5&#x000a0;ng for G&#x003b2;WT and 1, 5, and 10&#x000a0;ng for G&#x003b2;L95P in the presence of GIRK1/2 channels. Plasma membrane patches were stained with an antibody against G&#x003b2;<sub>1</sub>. Membranes are seen as brighter-colored areas, and the background is black. (<italic>PM</italic>, plasma membrane; <italic>bckd</italic>, background). Number of frog donors (N) = 1. <bold>(B)</bold> Surface expression of G&#x003b2;WT and G&#x003b2;L95P mutant in the presence of GIRK1/2, measured in GMP. Data shown are the mean fluorescence intensity produced by the expressed G&#x003b2;, after subtraction of the average signal observed in channel alone oocytes (GMP, giant membrane patches). Statistical analysis: one-way ANOVA ####p &#x0003c; 0.0001, ###p &#x0003c; 0.001, ##p &#x0003c; 0.01, and #p &#x0003c; 0.05 relative to channel-only group and ****p &#x0003c; 0.0001, ***p &#x0003c; 0.001, **p &#x0003c; 0.01, and *p &#x0003c; 0.05 relative to G&#x003b2;WT. <bold>(C)</bold> Representative current traces of GIRK1/2 channels. <bold>(D)</bold> Summary of GIRK1/2 activation by G&#x003b2;WT and G&#x003b2;L95P. Statistical analysis: one-way ANOVA ####p &#x0003c; 0.0001, ###p &#x0003c; 0.001, ##p &#x0003c; 0.01, and #p &#x0003c; 0.05 relative to channel-only group and ****p &#x0003c; 0.0001, ***p &#x0003c; 0.001, **p &#x0003c; 0.01, and *p &#x0003c; 0.05 relative to G&#x003b2;WT.</p></caption><graphic xlink:href="fphar-16-1592012-g002" position="float"/></fig></sec><sec id="s3-2"><title>G&#x003b2;<sub>1</sub>-L95P fails to activate GIRK channels even when the protein levels are similar to WT G&#x003b2;<sub>1</sub>
</title><p>Having established that expression levels comparable to WT G&#x003b2;<sub>1</sub> (1&#x000a0;ng RNA) can be achieved for G&#x003b2;<sub>1</sub>-L95P with a higher dose (10&#x000a0;ng RNA), we proceeded to investigate the ability of G&#x003b2;<sub>1</sub>-L95P (coexpressed with WT G&#x003b3;) to activate GIRK2 (<xref rid="F1" ref-type="fig">Figures 1C,D</xref>) and GIRK1/2 (<xref rid="F2" ref-type="fig">Figures 2C,D</xref>) channels. Despite achieving sufficient expression, G&#x003b2;<sub>1</sub>-L95P failed to activate both GIRK2 and GIRK1/2 channels.</p></sec><sec id="s3-3"><title>
<italic>GNB1</italic> L95P does not reduce the expression of GIRK channels in the membrane</title><p>When levels of expression of G&#x003b2;L95P and G&#x003b2;WT were close to each other, G&#x003b2;L95P failed to activate the channels. As decreased channel expression could yield a similar outcome, our subsequent focus was on investigating the effect of L95P on channel expression in the plasma membrane. We expressed YFP-labeled GIRK channels together with either WT G&#x003b2;<sub>1</sub> or G&#x003b2;<sub>1</sub>-L95P. The measurement of fluorescence intensity served as a reporter of channel density.</p><p>Our findings revealed a &#x0223c;2-fold increase in GIRK2-YFP channel expression in oocytes expressing either mutant or wild-type G&#x003b2;&#x003b3; (<xref rid="F3" ref-type="fig">Figures 3A,B</xref>). On the other hand, there was no significant change in YFP-GIRK1/2 expression when compared to channel density without G&#x003b2;&#x003b3; co-expression, regardless of whether G&#x003b2;&#x003b3; was wild type or L95P (<xref rid="F4" ref-type="fig">Figures 4A,B</xref>). Importantly, the selected RNA doses ensured comparable expression levels for both WT G&#x003b2;<sub>1</sub> and G&#x003b2;<sub>1</sub>-L95P.</p><fig position="float" id="F3"><label>FIGURE 3</label><caption><p>
<bold>(A)</bold> Representative confocal images of oocytes expressing GIRK2-YFP channels. <bold>(B)</bold> Surface expression of GIRK2-YFP channels in the presence of G&#x003b2;WT (1&#x000a0;ng) and G&#x003b2;L95P (10&#x000a0;ng) mutant. Data shown are the mean fluorescence intensity produced by the expressed GIRK2, after subtraction of the average signal observed in native oocytes (<italic>ooct</italic>, oocyte; <italic>bckd</italic>, background). <bold>(C)</bold> Representative current traces of GIRK2-YFP channels. <bold>(D)</bold> Summary of GIRK2 activation by G&#x003b2;WT (1&#x000a0;ng) and G&#x003b2;L95P (10&#x000a0;ng). Statistical analysis: one-way ordinary ANOVA (Tukey&#x02019;s test) or Kruskal&#x02013;Wallis test ####p &#x0003c; 0.0001, ###p &#x0003c; 0.001, ##p &#x0003c; 0.01, and #p &#x0003c; 0.05 relative to channel-only group and ****p &#x0003c; 0.0001, ***p &#x0003c; 0.001, **p &#x0003c; 0.01, and *p &#x0003c; 0.05 relative to G&#x003b2;WT; ns, not significant. Number of frog donors (N) = 1.</p></caption><graphic xlink:href="fphar-16-1592012-g003" position="float"/></fig><fig position="float" id="F4"><label>FIGURE 4</label><caption><p>
<bold>(A)</bold> Representative confocal images of oocytes expressing YFP-GIRK1/2 channels. <bold>(B)</bold> Surface expression of YFP-GIRK1/2 channels in the presence of G&#x003b2;WT (1&#x000a0;ng) and G&#x003b2;L95P (10&#x000a0;ng) mutant. Data shown are the mean fluorescence intensity produced by the expressed GIRK1/2 (<italic>ooct</italic>, oocyte; <italic>bckd</italic>, background). <bold>(C)</bold> Representative current traces of YFP-GIRK1/2 channels. <bold>(D)</bold> Summary of GIRK1/2 activation by G&#x003b2;WT (1&#x000a0;ng) and G&#x003b2;L95P (10&#x000a0;ng). Statistical analysis: one-way ordinary ANOVA (Tukey&#x02019;s test) ****p &#x0003c; 0.0001, ***p &#x0003c; 0.001, **p &#x0003c; 0.01, and *p &#x0003c; 0.05; ns, not significant. Number of frog donors (N) = 1.</p></caption><graphic xlink:href="fphar-16-1592012-g004" position="float"/></fig><p>Simultaneous electrophysiological experiments revealed a lack of channel activation by G&#x003b2;<sub>1</sub>-L95P, as demonstrated in both GIRK2 (<xref rid="F3" ref-type="fig">Figures 3C,D</xref>) and GIRK1/2 (<xref rid="F4" ref-type="fig">Figures 4C,D</xref>), when the channel expression in the membrane was unaltered or even increased compared to WT G&#x003b2;<sub>1</sub>.</p></sec><sec id="s3-4"><title>Structural analysis of L95P mutation</title><p>Initially, we analyzed the existing crystal structure of GIRK2&#x02013;G&#x003b2;&#x003b3; complex (protein data bank accession number 4kfm). Based on coordinates from 4kfm, we generated the list of amino acids that are expected to be in the interface between GIRK2 and G&#x003b2;&#x003b3; utilizing the PRODIGY server (in <xref rid="F5" ref-type="fig">Figure 5A</xref>, the amino acids in the interface between GIRK2 and G&#x003b2;&#x003b3; are shown as surfaces and L95 is shown as spheres). Notably, in the case of 4kfm, L95 is in the GIRK2&#x02013;G&#x003b2;&#x003b3; interface (<xref rid="F5" ref-type="fig">Figure 5B</xref>). Subsequently, we utilized the same criterion as in the PRODIGY algorithm (distance equal or less than 5.5 &#x0212b;) in order to generate a contact list of possible contacts of L95, utilizing the INTAA server (<xref rid="F5" ref-type="fig">Figure 5C</xref>). This assumption seems to be reasonable in light of the length of a non-covalent interaction (<xref rid="B23" ref-type="bibr">Kessel and Ben-Tal, 2018</xref>). Based on this list, we estimated the possible network of amino acids and non-covalent interactions of L95 utilizing the RINMAKER server (<xref rid="F5" ref-type="fig">Figure 5D</xref>). A summary of amino acids network interacting with L95 is provided in <xref rid="s11" ref-type="sec">Supplementary Table S1</xref>. The analysis procedure mentioned above was repeated for L95P mutation-containing structure that was generated on the base of 4kfm coordinates utilizing protein MutationExplorer server implementing the fixbb function of Rosetta for energy minimization. A cartoon representation of the expected structure of L95P mutant is shown in <xref rid="F5" ref-type="fig">Figure 5E</xref>. Similar to the above, amino acid network and interface analysis were also conducted for the mutant structure (<xref rid="F5" ref-type="fig">Figures 5F&#x02013;H</xref> and <xref rid="s11" ref-type="sec">Supplementary Table S1</xref>). It can be seen that there is a considerable decrease in amino acids expected to interact with proline in position 95 than with wild-type leucine. Moreover, we conducted limited analysis of the energetic impact of L95P mutation utilizing the MCSM server. It can be seen from <xref rid="F8" ref-type="fig">Figure 8C</xref> that L95P mutation has an energetically significant impact on 4kfm stability. However, the effect of this mutation on GIRK2&#x02013;G&#x003b2;&#x003b3; interaction affinity is expected to be rather modest and is near the thermal noise threshold.</p><fig position="float" id="F5"><label>FIGURE 5</label><caption><p>Structural analysis of the impact of L95P mutation on GIRK2-G&#x003b2;&#x003b3; complex. <bold>(A)</bold> Crystal structure of GIRK2&#x02013;G&#x003b2;&#x003b3; complex (obtained from 4KFM, three&#x000a0;G&#x003b2;&#x003b3; molecules were removed); L95 is shown as spheres and colored magenta. <bold>(B)</bold> Interface of GIRK&#x02013;G&#x003b2;&#x003b3; complex, with data generated by the PRODIGY server; selection criterion: all amino acids &#x02264;5.5 &#x0212b;. The left plot corresponds to the chain colored red in A, and the right plot corresponds to the chain marked orange in <bold>(A)</bold>. Note that L95 is in contact with some amino acids from the chain marked red. <bold>(C)</bold> Amino acids in contact with L95, same criterion as in B, with data obtained from analysis of GIRK&#x02013;G&#x003b2;&#x003b3; wild-type utilizing the INTAA server. Amino acids that belong to G&#x003b2; are colored blue, and amino acids that belong to GIRK2 are marked red. <bold>(D)</bold> Analysis of non-covalent interactions of amino acids that are expected to be in contact with L95 (data shown in <bold>C</bold>); network is generated by the RINMAKER server. Specific interactions of L95 are summarized in <xref rid="s11" ref-type="sec">Supplementary Table S1</xref>. <bold>(E)</bold> Predicted coordinates of GIRK2&#x02013;G&#x003b2;<sub>L95P</sub>&#x003b3; complex, with data generated by the MutationExplorer server utilizing fast Rosetta fixbb function; P95 is shown as spheres and colored magenta. <bold>(F)</bold> Interface of GIRK&#x02013;G&#x003b2;<sub>L95P</sub>&#x003b3; complex, with data generated by the PRODIGY server; selection criterion: all amino acids &#x02264;5.5 &#x0212b;. The left plot corresponds to the chain colored red in E, and the right plot corresponds to the chain colored orange in <bold>(E)</bold>. Note that P95 is in contact with the chain marked red. <bold>(G)</bold> Amino acids in contact with P95, same criterion as in F, with data obtained from analysis of GIRK&#x02013;G&#x003b2;<sub>L95P</sub>&#x003b3; utilizing the INTAA server. Amino acids that belong to G&#x003b2; are colored blue, and amino acids that belong to GIRK2 are colored red. <bold>(H)</bold> Analysis of non-covalent interactions of amino acids that are expected to be in contact with P95 (data shown in G); network is generated by the RINMAKER server. Specific interactions of P95 are summarized in <xref rid="s11" ref-type="sec">Supplementary Table S1</xref>.</p></caption><graphic xlink:href="fphar-16-1592012-g005" position="float"/></fig></sec><sec id="s3-5"><title>Analysis of docked GIRK1/2&#x02013;G&#x003b2;&#x003b3; structures</title><p>In order to investigate energetic and structural consequences of the L95P mutation for a heterotetrameric GIRK channel, we analyzed a predicted model of GIRK1/2&#x02013;G&#x003b2;&#x003b3; complex that was generated utilizing homology modeling and docking methods. We utilized the model of GIRK1/2 published by <xref rid="B13" ref-type="bibr">Gazgalis et al. (2022)</xref> and generated a rigid body docking model of GIRK1/2&#x02013;G&#x003b2;&#x003b3; (see Materials and Methods). We implemented selection criteria similar to those described by <xref rid="B31" ref-type="bibr">Mahajan et al. (2013)</xref> in order to assure acceptable location of G&#x003b2;&#x003b3; relative to the plasma membrane. This procedure rendered 19 model clusters (see Materials and Methods), of which two models, which correspond to centroids of the largest cluster and the cluster with the best energy score, were further analyzed (<xref rid="F6" ref-type="fig">Figures 6</xref>, <xref rid="F7" ref-type="fig">7</xref>).</p><fig position="float" id="F6"><label>FIGURE 6</label><caption><p>Structural analysis of the impact of L95P mutation on GIRK1/2&#x02013;G&#x003b2;&#x003b3; complex. Analysis was conducted utilizing coordinates of the best scoring GIRK1/2&#x02013;G&#x003b2;&#x003b3; complex. <bold>(A)</bold> Predicted structure of wild-type GIRK1/2&#x02013;G&#x003b2;&#x003b3; complex (single G&#x003b2;&#x003b3; molecule is docked); L95 is shown as spheres and colored magenta, GIRK1 subunits are colored red, and GIRK2 subunits are colored orange. <bold>(B)</bold> Interface of GIRK&#x02013;G&#x003b2;&#x003b3; complex, with data generated by the PRODIGY server; selection criterion: all amino acids are at &#x02264;5.5 &#x0212b; distance. The upper plot corresponds to GIRK1&#x02013;G&#x003b2;&#x003b3; interface. The lower plot corresponds to GIRK2&#x02013;G&#x003b2;&#x003b3; interface. Note that L95 is neither in GIRK1 nor in GIRK2 interface. <bold>(C)</bold> Amino acids in contact with L95, same criterion as in <bold>(B)</bold>, with data obtained from analysis of GIRK1/2&#x02013;G&#x003b2;&#x003b3; wild-type utilizing the INTAA server. As L95 is not part of the channel&#x02013;G&#x003b2;&#x003b3; interface, only amino acids that belong to G&#x003b2;&#x003b3; are shown. <bold>(D)</bold> Analysis of non-covalent interactions of amino acids expected to be in contact with L95 (data shown in <bold>C</bold>); network is generated by the RINMAKER server. Specific interactions of L95 are summarized in <xref rid="s11" ref-type="sec">Supplementary Table S1</xref>. <bold>(E)</bold> Predicted structure of GIRK1/2&#x02013;G&#x003b2;<sub>L95P</sub>&#x003b3; complex, with data generated by the MutationExplorer server utilizing fast Rosetta fixbb function; P95 is shown as spheres and colored magenta. <bold>(F)</bold> Interface of GIRK&#x02013;G&#x003b2;<sub>L95P</sub>&#x003b3; complex, with data generated by the PRODIGY server; selection criterion: all amino acids are at &#x02264;5.5 &#x0212b; distance. The upper plot corresponds to GIRK1&#x02013;G&#x003b2;<sub>L95P</sub>&#x003b3; interface, and the lower plot corresponds to GIRK2&#x02013;G&#x003b2;<sub>L95P</sub>&#x003b3; interface. Note that P95 is neither in GIRK1 nor in GIRK2 interface. <bold>(G)</bold> Amino acids in contact with P95, same criterion as in <bold>(F)</bold>, with data obtained from analysis of GIRK&#x02013;G&#x003b2;<sub>L95P</sub>&#x003b3; utilizing the INTAA server. Only amino acids that belong to G&#x003b2;&#x003b3; are shown. <bold>(H)</bold> Analysis of non-covalent interactions of amino acids that are expected to be in contact with P95 (data shown in <bold>(G)</bold>); network is generated by the RINMAKER server. Specific interactions of P95 are summarized in <xref rid="s11" ref-type="sec">Supplementary Table S1</xref>.</p></caption><graphic xlink:href="fphar-16-1592012-g006" position="float"/></fig><fig position="float" id="F7"><label>FIGURE 7</label><caption><p>Structural analysis of impact of L95P mutation on GIRK1/2&#x02013;G&#x003b2;&#x003b3; complex. Analysis was conducted utilizing coordinates of the largest cluster of GIRK1/2&#x02013;G&#x003b2;&#x003b3; complex. <bold>(A)</bold> Structure of wild-type GIRK1/2&#x02013;G&#x003b2;&#x003b3; complex (single G&#x003b2;&#x003b3; molecule is docked); L95 is shown as spheres and colored magenta, GIRK1 subunits are colored red, and GIRK2 subunits are colored orange. <bold>(B)</bold> Interface of GIRK&#x02013;G&#x003b2;&#x003b3; complex, with data generated by the PRODIGY server; selection criterion: all amino acids &#x02264;5.5 &#x0212b;. The upper plot corresponds to GIRK1&#x02013;G&#x003b2;&#x003b3; interface. The lower plot corresponds to GIRK2&#x02013;G&#x003b2;&#x003b3; interface. Note that L95 is neither in GIRK1 nor in GIRK2 interface. <bold>(C)</bold> Amino acids in contact with L95, same criterion as in B, with data obtained from analysis of GIRK1/2&#x02013;G&#x003b2;&#x003b3; wild-type utilizing the INTAA server. Only amino acids that belong to G&#x003b2;&#x003b3; are shown. <bold>(D)</bold> Analysis of non-covalent interactions of amino acids that are expected to be in contact with L95 (data shown in <bold>(C)</bold>); network is generated by the RINMAKER server. Specific interactions of L95 are summarized in <xref rid="s11" ref-type="sec">Supplementary Table S1</xref>. <bold>(E)</bold> Predicted coordinates of GIRK1/2&#x02013;G&#x003b2;<sub>L95P</sub>&#x003b3; complex, with data generated by the MutationExplorer server utilizing fast Rosetta fixbb function; P95 is shown as spheres and colored magenta. <bold>(F)</bold> Interface of GIRK&#x02013;G&#x003b2;<sub>L95P</sub>&#x003b3; complex, with data generated by the PRODIGY server; selection criterion: all amino acids &#x02264;5.5 &#x0212b;. The upper plot corresponds GIRK1&#x02013;G&#x003b2;<sub>L95P</sub>&#x003b3; interface, and the lower plot corresponds to GIRK2&#x02013;G&#x003b2;<sub>L95P</sub>&#x003b3; interface. Note that P95 is neither in GIRK1 nor in GIRK2 interface. <bold>(G)</bold> Amino acids in contact with P95, same criterion as in F, with data obtained from analysis of GIRK&#x02013;G&#x003b2;<sub>L95P</sub>&#x003b3; utilizing the INTAA server. Only amino acids that belong to G&#x003b2;&#x003b3; are shown. <bold>(H)</bold> Analysis of non-covalent interactions of amino acids that are expected to be in contact with P95 (data shown in <bold>(G)</bold>); network is generated by the RINMAKER server. Specific interactions of P95 are summarized in <xref rid="s11" ref-type="sec">Supplementary Table S1</xref>.</p></caption><graphic xlink:href="fphar-16-1592012-g007" position="float"/></fig><p>Analysis of the two selected GIRK1/2&#x02013;G&#x003b2;&#x003b3; models, based on the centroid of the largest cluster (lc) and the best energy score (bs), revealed that in both cases, L95 is not part of the GIRK&#x02013;G&#x003b2;&#x003b3; interface (<xref rid="F6" ref-type="fig">Figures 6</xref>, <xref rid="F7" ref-type="fig">7</xref>). This was consistent across both models, suggesting that the interaction between GIRK1/2 and G&#x003b2;&#x003b3; differs from that observed in the GIRK2&#x02013;G&#x003b2;&#x003b3; complex. Additionally, the impact of L95P mutation on amino acids network interacting with that in position 95 in both models is quite similar to that observed for the 4kfm crystal structure. From <xref rid="s11" ref-type="sec">Supplementary Table S1</xref>, it can be seen that at least seven amino acids interact with the wild-type leucine in position 95, whereas 2&#x02013;4 amino acids remain interacting with proline in the same position in the mutant G&#x003b2;. In addition, from the energetic point of view, L95P is expected to be highly destabilizing for both GIRK1/2&#x02013;G&#x003b2;&#x003b3; predicted models, whereas the effect of this mutation on G&#x003b2;&#x003b3;&#x02013;GIRK1/2 interaction affinity is near the thermal noise threshold (<xref rid="F8" ref-type="fig">Figure 8C</xref>).</p><fig position="float" id="F8"><label>FIGURE 8</label><caption><p>Structural analysis of the impact of L95P mutation on G&#x003b2;&#x003b3;&#x02212;effector complexes. <bold>(A)</bold> Colored scale representation of G&#x003b2;<sub>1</sub> generated in the ConSurf server (<xref rid="B1" ref-type="bibr">Ashkenazy et al., 2016</xref>). The scale is 1&#x02013;9 with more evolutionary conserved amino acids colored by a more darker color. L95 is shown as spheres. <bold>(B)</bold> G&#x003b2;&#x003b3;&#x02212;effector interface analysis. All interfaces are generated by the PRODIGY server. L95 is shown as red spheres; upper left&#x02014;G&#x003b1;1GDPG&#x003b2;&#x003b3; (1gp2), upper right&#x02014;&#x003b2;-adrenergic kinase&#x02013;G&#x003b2;&#x003b3; complex (1omw), lower left&#x02014;phosducin&#x02013;G&#x003b2;&#x003b3; complex (2trc), and lower right&#x02014;TRPM3&#x02013;G&#x003b2;&#x003b3; (6rmv). <bold>(C)</bold> Effect of L95P mutation on protein stability and G&#x003b2;&#x003b3; affinity, GIRK crystal structure, and models. <bold>(D)</bold> Effect of L95P mutation on protein stability and G&#x003b2;&#x003b3; affinity and other effectors. All data in <bold>(C,D)</bold> were calculated utilizing the MCSM server.</p></caption><graphic xlink:href="fphar-16-1592012-g008" position="float"/></fig></sec><sec id="s3-6"><title>Analysis of L95P mutation in other structures</title><p>In order to further understand the possible role of L95P mutation in G&#x003b2;<sub>1</sub>, we conducted structural and energetic analysis of this mutation in isolated G&#x003b2;<sub>1</sub> and also in other crystal structures that contain this or homologous proteins. In particular, we analyzed the crystal structures of &#x003b2;-adrenergic kinase2 (&#x003b2;-ARK)-G&#x003b2;&#x003b3; (1omw) (<xref rid="B47" ref-type="bibr">Thal et al., 2011</xref>; <xref rid="B46" ref-type="bibr">Tesmer et al., 2010</xref>; <xref rid="B27" ref-type="bibr">Lodowski et al., 2003</xref>), G&#x003b1;<sub>i1</sub>-G&#x003b2;&#x003b3; (1gp2) (<xref rid="B50" ref-type="bibr">Wall et al., 1995</xref>), and TRPM3- G&#x003b2;&#x003b3; (6rmv) (<xref rid="B3" ref-type="bibr">Behrendt et al., 2020</xref>) complexes and also of the phosducin-G&#x003b2;&#x003b3; complex (2trc) (<xref rid="B12" ref-type="bibr">Gaudet et al., 1996</xref>).</p><p>Initially, we analyzed the evolutional conservation of amino acids in G&#x003b2;<sub>1</sub> utilizing the ConSurf server (<xref rid="F8" ref-type="fig">Figure 8A</xref>), yielding L95 to be a highly conserved residue (color scale 8 with normalized conservation score of &#x02013; 0.897). Thereafter, we studied the role of L95 in G&#x003b2;&#x003b3; interactions with other effectors mentioned above. We utilized the PRODIGY webserver for the detection of amino acids present in the protein&#x02013;protein interface. The protein&#x02013;protein interfaces for these structures are shown in <xref rid="F8" ref-type="fig">Figure 8B</xref>. Out of four examined structures, L95 was found in the protein&#x02013;protein interface only in one (&#x003b2;-ARK-G&#x003b2;&#x003b3;, 1omw).</p><p>Consequently, we estimated the possible impact of L95P mutation on protein stability and protein&#x02013;protein affinity (<xref rid="F8" ref-type="fig">Figure 8D</xref>). It can be seen that in all structures, the predicted energetic cost of the mutation is higher than the RT value at 25 C<sup>o</sup> (0.6&#x000a0;kcal/mol), and for the &#x003b2;-ARK-G&#x003b2;&#x003b3; complex, it is higher than 1.4&#x000a0;kcal/mol. On the other hand, the predicted impact of L95P mutation on affinity change is rather low, &#x0223c;0.6&#x000a0;kcal/mol (very close to the RT value, which is considered to be close to thermal noise effect).</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>In order to study the effect of L95P mutation, we utilized heterologous expression (<italic>X. laevis</italic> oocytes), which enables strict control on both protein level expression and comparison of various possible ligand&#x02013;effector pairs (<xref rid="B9" ref-type="bibr">Dascal and Lotan, 1992</xref>). We demonstrated that the L95P mutation exerts a dual effect by impairing both the expression and function of G&#x003b2;<sub>1</sub> as a GIRK channel activating molecule. Our heterologous expression experiments revealed a clear reduction in expression levels of the G&#x003b2;<sub>1</sub> protein, requiring significantly higher amounts of L95P mRNA than wild-type G&#x003b2;&#x003b3; RNA to achieve similar expression in the plasma membrane (<xref rid="F1" ref-type="fig">Figures 1B</xref>, <xref rid="F3" ref-type="fig">3B</xref>). In addition to the loss of expression, we have shown that L95P mutation also impairs GIRK channel function. Such a combined effect of mutation both on protein expression and protein function has been described for other G&#x003b2;<sub>1</sub> mutations by <xref rid="B37" ref-type="bibr">Reddy et al. (2021)</xref>. Electrophysiological experiments with GIRK2 and GIRK1/2 channels showed that even when L95P expression levels matched those of wild-type G&#x003b2;&#x003b3;, the mutant protein failed to produce equivalent current levels.</p><p>The loss of expression effect is also supported by structural analysis as we demonstrated a destabilizing impact of L95P mutation observed in both the 4kfm crystal structure of GIRK2&#x02013;G&#x003b2;&#x003b3; complex and in the predicted models of GIRK1/2&#x02013;G&#x003b2;&#x003b3;. A similar effect was also shown for other G&#x003b2;&#x003b3;&#x02013;effector complexes. This phenomenon, that is, protein misfolding that results from point mutation and subsequent rapid degradation, is described in many known pathologies such as phenylketonuria, cystic fibrosis, short chain acyl-CoA dehydrogenase deficiency disease (<xref rid="B14" ref-type="bibr">Gregersen et al., 2000</xref>), and others.</p><p>The loss of function effect of L95P mutation is more difficult to explain. In general, ion channel activity (formulated as open probability, for example) is assumed to be a function of maximal open probability and some kind of either hyperbolic or, in more complicated cases, sigmoid function which consists of an efficacy parameter and the concentration of activating ligand (<xref rid="B19" ref-type="bibr">Hille, 2001</xref>). In the case of GIRK channels, such a relationship includes channel affinity to G&#x003b2;&#x003b3;, maximal open probability, and allosteric coefficients relevant to channel activity changes due to binding of several G&#x003b2;&#x003b3; subunits (<xref rid="B48" ref-type="bibr">Touhara et al., 2016</xref>; <xref rid="B51" ref-type="bibr">Wang et al., 2016</xref>). According to the analysis of various G&#x003b2;&#x003b3; effectors, including GIRK2 (from existing crystal structure) and GIRK1/2 (from predicted models), there is no substantial change in G&#x003b2;&#x003b3; affinity to the channel induced by L95P mutation.</p><p>The aforementioned findings may have several interpretations, and among them is an impact of L95P on the maximal open probability of GIRK1/2 and GIRK2 in a situation similar to partial agonist scheme (<xref rid="B22" ref-type="bibr">Kenakin, 2009</xref>). However, this scenario does not agree well with all experimental findings. In a situation of similar affinity of L95P mutant to GIRK channel and lower maximal open probability, the expected effect of L95P expression would be a decrease of channel activity below the level observed before mutant co-expression. It must be taken into consideration that at least GIRK1/2 basal activity is highly (&#x0223c;90%) G&#x003b2;&#x003b3;-depedent, as it was shown by <xref rid="B40" ref-type="bibr">Rishal et al. (2005)</xref>. Correspondingly, the expression of L95P mutant with equal affinity to wild-type G&#x003b2;&#x003b3; and a reduced maximal open probability would lead to the appearance of two channel populations: one corresponding to the maximal open probability of wild-type G&#x003b2;&#x003b3; and the other to that of a mutant. Altogether, the above assumption of decreased maximal open probability and no change in G&#x003b2;&#x003b3; affinity to GIRK is expected to reduce the basal GIRK1/2 current, which was not observed experimentally.</p><p>At this point, we hypothesize that the loss of function effect of L95P mutation may also be associated with the protein misfolding phenomenon, which was described above as a reason for the loss of expression effect of L95P. Misfolded protein molecules frequently fail to interact with their receptors due to aberrant intracellular localization, aggregation, and removal by proofreading systems such as chaperons (<xref rid="B32" ref-type="bibr">Oikonomou and Hendershot, 2020</xref>). It must be emphasized that previously described mutations on G&#x003b2; (in particular I80T and I80N) were shown to also be loss of expression mutations (<xref rid="B37" ref-type="bibr">Reddy et al., 2021</xref>; <xref rid="B7" ref-type="bibr">Colombo et al., 2023</xref>), with possible similarity of L95P and I80T/N impact on protein stability.</p><p>In summary, the L95P mutation exerts a dual effect on the GIRK&#x02013;G&#x003b2;&#x003b3; system, affecting both protein density and function. Despite L95 not being directly involved in GIRK&#x02013;G&#x003b2;&#x003b3; structural interactions, the study highlights the importance of expression systems such as <italic>X. laevis</italic> oocytes in investigating disease-causing missense mutations. These systems allow precise control and measurement of protein expression and enable electrophysiological studies to assess the functional consequences of such mutations (<xref rid="B15" ref-type="bibr">Hatcher-Solis et al., 2014</xref>).</p><p>Detailed analysis of point mutations effect on the G-protein subunit&#x02013;effector interaction conducted in this study and in other studies such as those for G&#x003b2;&#x003b3; (<xref rid="B37" ref-type="bibr">Reddy et al., 2021</xref>; <xref rid="B7" ref-type="bibr">Colombo et al., 2023</xref>) and those for G&#x003b1; (<xref rid="B24" ref-type="bibr">Knight et al., 2023</xref>) can provide important information for further development of treatment strategies of complex medical conditions arising from those mutations (<xref rid="B43" ref-type="bibr">Shalomov et al., 2025</xref>).</p></sec></body><back><sec sec-type="data-availability" id="s5"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="s6"><title>Ethics statement</title><p>The animal study was approved by the Tel Aviv University Institutional Animal Care and Use Committee. The study was conducted in accordance with the local legislation and institutional requirements.</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>HR: conceptualization, data curation, formal analysis, investigation, methodology, project administration, software, supervision, validation, visualization, writing &#x02013; original draft, and writing &#x02013; review and editing. TK-R: data curation, investigation, writing &#x02013; original draft, and writing &#x02013; review and editing. GT: data curation, investigation, writing &#x02013; original draft, and writing &#x02013; review and editing. ND: conceptualization, data curation, funding acquisition, investigation, methodology, project administration, resources, supervision, validation, writing &#x02013; original draft, and writing &#x02013; review and editing. DY: conceptualization, data curation, formal analysis, investigation, methodology, software, supervision, validation, visualization, writing &#x02013; original draft, and writing &#x02013; review and editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec id="s12"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2025.1592012/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fphar.2025.1592012/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data"><media xlink:href="Table1.docx"/></supplementary-material><supplementary-material id="SM2" position="float" content-type="local-data"><media xlink:href="DataSheet1.pdf"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ashkenazy</surname><given-names>H.</given-names></name><name><surname>Abadi</surname><given-names>S.</given-names></name><name><surname>Martz</surname><given-names>E.</given-names></name><name><surname>Chay</surname><given-names>O.</given-names></name><name><surname>Mayrose</surname><given-names>I.</given-names></name><name><surname>Pupko</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules</article-title>. <source>Nucleic Acids Res.</source>
<volume>44</volume>, <fpage>W344</fpage>&#x02013;<lpage>W350</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkw408</pub-id>
<pub-id pub-id-type="pmid">27166375</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bassan</surname><given-names>H.</given-names></name><name><surname>Petrovski</surname><given-names>S.</given-names></name><name><surname>Bilancia</surname><given-names>C. G.</given-names></name><name><surname>Ramsey</surname><given-names>K.</given-names></name><name><surname>Griffin</surname><given-names>N. G.</given-names></name><name><surname>Bier</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Refining the phenotype associated with GNB1 mutations: Clinical data on 18 newly identified patients and review of the literature</article-title>. <source>Am. J. Med. Genet. A</source>
<volume>176</volume>, <fpage>2259</fpage>&#x02013;<lpage>2275</lpage>.<pub-id pub-id-type="pmid">30194818</pub-id>
</mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Behrendt</surname><given-names>M.</given-names></name><name><surname>Gruss</surname><given-names>F.</given-names></name><name><surname>Enzeroth</surname><given-names>R.</given-names></name><name><surname>Dembla</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Crassous</surname><given-names>P. A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The structural basis for an on-off switch controlling G&#x003b2;&#x003b3;-mediated inhibition of TRPM3 channels</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>117</volume>, <fpage>29090</fpage>&#x02013;<lpage>29100</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2001177117</pub-id>
<pub-id pub-id-type="pmid">33122432</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Berg</surname><given-names>J. M.</given-names></name><name><surname>Tymoczko</surname><given-names>J. L.</given-names></name><name><surname>Stryer</surname><given-names>L.</given-names></name></person-group> (<year>2012</year>). <source>Biochemistry/Jeremy M. Berg, John L. Tymoczko, Lubert Stryer; with Gregory J. Gatto, Jr</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>W. H. Freeman</publisher-name>.</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berlin</surname><given-names>S.</given-names></name><name><surname>Tsemakhovich</surname><given-names>V. A.</given-names></name><name><surname>Castel</surname><given-names>R.</given-names></name><name><surname>Ivanina</surname><given-names>T.</given-names></name><name><surname>Dessauer</surname><given-names>C. W.</given-names></name><name><surname>Keren-Raifman</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Two distinct aspects of coupling between G&#x003b1;(i) protein and G protein-activated K<sup>+</sup> channel (GIRK) revealed by fluorescently labeled G&#x003b1;(i3) protein subunits</article-title>. <source>J. Biol. Chem.</source>
<volume>286</volume>, <fpage>33223</fpage>&#x02013;<lpage>33235</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.271056</pub-id>
<pub-id pub-id-type="pmid">21795707</pub-id>
</mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Campos-Rios</surname><given-names>A.</given-names></name><name><surname>Rueda-Ruzafa</surname><given-names>L.</given-names></name><name><surname>Lamas</surname><given-names>J. A.</given-names></name></person-group> (<year>2022</year>). <article-title>The relevance of GIRK channels in heart function</article-title>. <source>Membranes</source>
<volume>12</volume>, <fpage>1119</fpage>. <pub-id pub-id-type="doi">10.3390/membranes12111119</pub-id>
<pub-id pub-id-type="pmid">36363674</pub-id>
</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Colombo</surname><given-names>S.</given-names></name><name><surname>Reddy</surname><given-names>H. P.</given-names></name><name><surname>Petri</surname><given-names>S.</given-names></name><name><surname>Williams</surname><given-names>D. J.</given-names></name><name><surname>Shalomov</surname><given-names>B.</given-names></name><name><surname>Dhindsa</surname><given-names>R. S.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Epilepsy in a mouse model of GNB1 encephalopathy arises from altered potassium (GIRK) channel signaling and is alleviated by a GIRK inhibitor</article-title>. <source>Front. Cell Neurosci.</source>
<volume>17</volume>, <fpage>1175895</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2023.1175895</pub-id>
<pub-id pub-id-type="pmid">37275776</pub-id>
</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cui</surname><given-names>M.</given-names></name><name><surname>Cantwell</surname><given-names>L.</given-names></name><name><surname>Zorn</surname><given-names>A.</given-names></name><name><surname>Logothetis</surname><given-names>D. E.</given-names></name></person-group> (<year>2021</year>). <article-title>Kir Channel molecular physiology, pharmacology, and therapeutic implications</article-title>. <source>pharmacology</source>
<volume>267</volume>, <fpage>277</fpage>&#x02013;<lpage>356</lpage>. <pub-id pub-id-type="doi">10.1007/164_2021_501</pub-id>
</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Dascal</surname><given-names>N.</given-names></name><name><surname>Lotan</surname><given-names>E.</given-names></name></person-group> (<year>1992</year>). <article-title>Expression of exogenous ion channels and neurotransmitter receptors in RNA-injected xenopus oocytes</article-title>. <source>Springer protocols. Series: Methods In Molecular Biology. Protocols in Molecular Neurobiology</source>. <publisher-loc>NJ</publisher-loc>: <publisher-name>Humana Totowa</publisher-name>
</mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Da Silva</surname><given-names>J. D.</given-names></name><name><surname>Costa</surname><given-names>M. D.</given-names></name><name><surname>Almeida</surname><given-names>B.</given-names></name><name><surname>Lopes</surname><given-names>F.</given-names></name><name><surname>Maciel</surname><given-names>P.</given-names></name><name><surname>Teixeira-Castro</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Case report: a novel GNB1 mutation causes global developmental delay with intellectual disability and behavioral disorders</article-title>. <source>Front. Neurol.</source>
<volume>12</volume>, <fpage>735549</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2021.735549</pub-id>
<pub-id pub-id-type="pmid">34646230</pub-id>
</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Endo</surname><given-names>W.</given-names></name><name><surname>Ikemoto</surname><given-names>S.</given-names></name><name><surname>Togashi</surname><given-names>N.</given-names></name><name><surname>Miyabayashi</surname><given-names>T.</given-names></name><name><surname>Nakajima</surname><given-names>E.</given-names></name><name><surname>Hamano</surname><given-names>S. I.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Phenotype-genotype correlations in patients with GNB1 gene variants, including the first three reported Japanese patients to exhibit spastic diplegia, dyskinetic quadriplegia, and infantile spasms</article-title>. <source>Brain Dev.</source>
<volume>42</volume>, <fpage>199</fpage>&#x02013;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2019.10.006</pub-id>
<pub-id pub-id-type="pmid">31735425</pub-id>
</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gaudet</surname><given-names>R.</given-names></name><name><surname>Bohm</surname><given-names>A.</given-names></name><name><surname>Sigler</surname><given-names>P. B.</given-names></name></person-group> (<year>1996</year>). <article-title>Crystal structure at 2.4 angstroms resolution of the complex of transducin betagamma and its regulator, phosducin</article-title>. <source>Phosducin Cell</source>
<volume>87</volume>, <fpage>577</fpage>&#x02013;<lpage>588</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(00)81376-8</pub-id>
<pub-id pub-id-type="pmid">8898209</pub-id>
</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gazgalis</surname><given-names>D.</given-names></name><name><surname>Cantwell</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Thakur</surname><given-names>G. A.</given-names></name><name><surname>Cui</surname><given-names>M.</given-names></name><name><surname>Guarnieri</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Use of a molecular switch probe to activate or inhibit GIRK1 heteromers <italic>in silico</italic> reveals a novel gating mechanism</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>23</volume>, <fpage>10820</fpage>. <pub-id pub-id-type="doi">10.3390/ijms231810820</pub-id>
<pub-id pub-id-type="pmid">36142730</pub-id>
</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gregersen</surname><given-names>N.</given-names></name><name><surname>Bross</surname><given-names>P.</given-names></name><name><surname>Jorgensen</surname><given-names>M. M.</given-names></name><name><surname>Corydon</surname><given-names>T. J.</given-names></name><name><surname>Andresen</surname><given-names>B. S.</given-names></name></person-group> (<year>2000</year>). <article-title>Defective folding and rapid degradation of mutant proteins is a common disease mechanism in genetic disorders</article-title>. <source>J. Inherit. Metab. Dis.</source>
<volume>23</volume>, <fpage>441</fpage>&#x02013;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1023/a:1005663728291</pub-id>
<pub-id pub-id-type="pmid">10947197</pub-id>
</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hatcher-Solis</surname><given-names>C.</given-names></name><name><surname>Fribourg</surname><given-names>M.</given-names></name><name><surname>Spyridaki</surname><given-names>K.</given-names></name><name><surname>Younkin</surname><given-names>J.</given-names></name><name><surname>Ellaithy</surname><given-names>A.</given-names></name><name><surname>Xiang</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>G protein-coupled receptor signaling to Kir channels in Xenopus oocytes</article-title>. <source>Curr. Pharm. Biotechnol.</source>
<volume>15</volume>, <fpage>987</fpage>&#x02013;<lpage>995</lpage>. <pub-id pub-id-type="doi">10.2174/1389201015666141031111916</pub-id>
<pub-id pub-id-type="pmid">25374032</pub-id>
</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hemati</surname><given-names>P.</given-names></name><name><surname>Revah-Politi</surname><given-names>A.</given-names></name><name><surname>Bassan</surname><given-names>H.</given-names></name><name><surname>Petrovski</surname><given-names>S.</given-names></name><name><surname>Bilancia</surname><given-names>C. G.</given-names></name><name><surname>Ramsey</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2018a</year>). <article-title>Refining the phenotype associated with GNB1 mutations: clinical data on 18 newly identified patients and review of the literature</article-title>. <source>Am. J. Med. Genet. A</source>
<volume>176</volume>, <fpage>2259</fpage>&#x02013;<lpage>2275</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.40472</pub-id>
<pub-id pub-id-type="pmid">30194818</pub-id>
</mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hemati</surname><given-names>P.</given-names></name><name><surname>Revah-Politi</surname><given-names>A.</given-names></name><name><surname>Bassan</surname><given-names>H.</given-names></name><name><surname>Petrovski</surname><given-names>S.</given-names></name><name><surname>Bilancia</surname><given-names>C. G.</given-names></name><name><surname>Ramsey</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2018b</year>). <article-title>Refining the phenotype associated with GNB1 mutations: clinical data on 18 newly identified patients and review of the literature</article-title>. <source>Am. J. Med. Genet. A</source>
<volume>176</volume>, <fpage>2259</fpage>&#x02013;<lpage>2275</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.40472</pub-id>
<pub-id pub-id-type="pmid">30194818</pub-id>
</mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hibino</surname><given-names>H.</given-names></name><name><surname>Inanobe</surname><given-names>A.</given-names></name><name><surname>Furutani</surname><given-names>K.</given-names></name><name><surname>Murakami</surname><given-names>S.</given-names></name><name><surname>Findlay</surname><given-names>I.</given-names></name><name><surname>Kurachi</surname><given-names>Y.</given-names></name></person-group> (<year>2010</year>). <article-title>Inwardly rectifying potassium channels: their structure, function, and physiological roles</article-title>. <source>Physiol. Rev.</source>
<volume>90</volume>, <fpage>291</fpage>&#x02013;<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00021.2009</pub-id>
<pub-id pub-id-type="pmid">20086079</pub-id>
</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Hille</surname><given-names>B.</given-names></name></person-group> (<year>2001</year>). <source>Ionic channels of excitable membranes</source>. <publisher-loc>Sunderland, MA</publisher-loc>: <publisher-name>Sinauer</publisher-name>.</mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>H. F.</given-names></name><name><surname>Morales-Brice&#x000f1;o</surname><given-names>H.</given-names></name><name><surname>Barwick</surname><given-names>K.</given-names></name><name><surname>Lewis</surname><given-names>J.</given-names></name><name><surname>Sanchis-Juan</surname><given-names>A.</given-names></name><name><surname>Raymond</surname><given-names>F. L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Myoclonus-dystonia caused by GNB1 mutation responsive to deep brain stimulation American</article-title>. <source>J. Med. Genet. Part A</source>
<volume>34</volume>, <fpage>1079</fpage>&#x02013;<lpage>1080</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.40472</pub-id>
</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kahanovitch</surname><given-names>U.</given-names></name><name><surname>Tsemakhovich</surname><given-names>V.</given-names></name><name><surname>Berlin</surname><given-names>S.</given-names></name><name><surname>Rubinstein</surname><given-names>M.</given-names></name><name><surname>Styr</surname><given-names>B.</given-names></name><name><surname>Castel</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Recruitment of G&#x003b2;&#x003b3; controls the basal activity of G-protein coupled inwardly rectifying potassium (GIRK) channels: crucial role of distal C terminus of GIRK1</article-title>. <source>J. Physiol.</source>
<volume>592</volume>, <fpage>5373</fpage>&#x02013;<lpage>5390</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2014.283218</pub-id>
<pub-id pub-id-type="pmid">25384780</pub-id>
</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Kenakin</surname><given-names>T. P.</given-names></name></person-group> (<year>2009</year>). <source>A pharmacology primer: theory, applications, and methods</source>. <article-title>Cambridge, MA</article-title>: <publisher-name>Academic Press/Elsevier</publisher-name>.</mixed-citation></ref><ref id="B23"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Kessel</surname><given-names>A.</given-names></name><name><surname>Ben-Tal</surname><given-names>N.</given-names></name></person-group> (<year>2018</year>). <source>Introduction to proteins: structure, function, and motion</source>. <article-title>Boca Raton, FL</article-title>: <publisher-name>Chapman and Hall/CRC</publisher-name>.</mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Knight</surname><given-names>K. M.</given-names></name><name><surname>Obarow</surname><given-names>E. G.</given-names></name><name><surname>Wei</surname><given-names>W.</given-names></name><name><surname>Mani</surname><given-names>S.</given-names></name><name><surname>Esteller</surname><given-names>M. I.</given-names></name><name><surname>Cui</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Molecular annotation of G protein variants in a neurological disorder</article-title>, <source>Cell Rep.</source>
<volume>42</volume>, <fpage>113462</fpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2023.113462</pub-id>
<pub-id pub-id-type="pmid">37980565</pub-id>
</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kozakov</surname><given-names>D.</given-names></name><name><surname>Hall</surname><given-names>D. R.</given-names></name><name><surname>Xia</surname><given-names>B.</given-names></name><name><surname>Porter</surname><given-names>K. A.</given-names></name><name><surname>Padhorny</surname><given-names>D.</given-names></name><name><surname>Yueh</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>The ClusPro web server for protein-protein docking</article-title>. <source>Nat. Protoc.</source>
<volume>12</volume>, <fpage>255</fpage>&#x02013;<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2016.169</pub-id>
<pub-id pub-id-type="pmid">28079879</pub-id>
</mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lansdon</surname><given-names>L. A.</given-names></name><name><surname>Saunders</surname><given-names>C. J.</given-names></name></person-group> (<year>2021</year>). <article-title>Genotype-phenotype correlation in GNB1-related neurodevelopmental disorder: potential association of p.Leu95Pro with cleft palate</article-title>. <source>Am. J. Med. Genet. A</source>
<volume>185</volume>, <fpage>1341</fpage>&#x02013;<lpage>1343</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.62080</pub-id>
<pub-id pub-id-type="pmid">33427398</pub-id>
</mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lodowski</surname><given-names>D. T.</given-names></name><name><surname>Pitcher</surname><given-names>J. A.</given-names></name><name><surname>Capel</surname><given-names>W. D.</given-names></name><name><surname>Lefkowitz</surname><given-names>R. J.</given-names></name><name><surname>Tesmer</surname><given-names>J. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Keeping G proteins at bay: a complex between G protein-coupled receptor kinase 2 and Gbetagamma</article-title>. <source>Science</source>
<volume>300</volume>, <fpage>1256</fpage>&#x02013;<lpage>1262</lpage>. <pub-id pub-id-type="doi">10.1126/science.1082348</pub-id>
<pub-id pub-id-type="pmid">12764189</pub-id>
</mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Logothetis</surname><given-names>D. E.</given-names></name><name><surname>Kurachi</surname><given-names>Y.</given-names></name><name><surname>Galper</surname><given-names>J.</given-names></name><name><surname>Neer</surname><given-names>E. J.</given-names></name><name><surname>Clapham</surname><given-names>D. E.</given-names></name></person-group> (<year>1987</year>). <article-title>The beta gamma subunits of GTP-binding proteins activate the muscarinic K+ channel in heart</article-title>. <source>Nature</source>
<volume>325</volume>, <fpage>321</fpage>&#x02013;<lpage>326</lpage>. <pub-id pub-id-type="doi">10.1038/325321a0</pub-id>
<pub-id pub-id-type="pmid">2433589</pub-id>
</mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lomize</surname><given-names>M. A.</given-names></name><name><surname>Pogozheva</surname><given-names>I. D.</given-names></name><name><surname>Joo</surname><given-names>H.</given-names></name><name><surname>Mosberg</surname><given-names>H. I.</given-names></name><name><surname>Lomize</surname><given-names>A. L.</given-names></name></person-group> (<year>2012</year>). <article-title>OPM database and PPM web server: resources for positioning of proteins in membranes</article-title>. <source>Nucleic acids Res.</source>
<volume>40</volume>, <fpage>D370</fpage>&#x02013;<lpage>D376</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkr703</pub-id>
<pub-id pub-id-type="pmid">21890895</pub-id>
</mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luo</surname><given-names>H.</given-names></name><name><surname>Marron Fernandez de Velasco</surname><given-names>E.</given-names></name><name><surname>Wickman</surname><given-names>K.</given-names></name></person-group> (<year>2022</year>). <article-title>Neuronal G protein-gated K(+) channels</article-title>. <source>Am. J. Physiol. Cell Physiol.</source>
<volume>323</volume>, <fpage>C439</fpage>&#x02013;<lpage>C460</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00102.2022</pub-id>
<pub-id pub-id-type="pmid">35704701</pub-id>
</mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mahajan</surname><given-names>R.</given-names></name><name><surname>Ha</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Kawano</surname><given-names>T.</given-names></name><name><surname>Kozasa</surname><given-names>T.</given-names></name><name><surname>Logothetis</surname><given-names>D. E.</given-names></name></person-group> (<year>2013</year>). <article-title>A computational model predicts that G&#x003b2;&#x003b3; acts at a cleft between channel subunits to activate GIRK1 channels</article-title>. <source>Sci. Signal</source>
<volume>6</volume>, <fpage>ra69</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.2004075</pub-id>
<pub-id pub-id-type="pmid">23943609</pub-id>
</mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oikonomou</surname><given-names>C.</given-names></name><name><surname>Hendershot</surname><given-names>L. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Disposing of misfolded ER proteins: a troubled substrate's way out of the ER</article-title>. <source>Mol. Cell Endocrinol.</source>
<volume>500</volume>, <fpage>110630</fpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2019.110630</pub-id>
<pub-id pub-id-type="pmid">31669350</pub-id>
</mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oldham</surname><given-names>W. M.</given-names></name><name><surname>Hamm</surname><given-names>H. E.</given-names></name></person-group> (<year>2008</year>). <article-title>Heterotrimeric G protein activation by G-protein-coupled receptors</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source>
<volume>9</volume>, <fpage>60</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2299</pub-id>
<pub-id pub-id-type="pmid">18043707</pub-id>
</mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petrovski</surname><given-names>S.</given-names></name><name><surname>K&#x000fc;ry</surname><given-names>S.</given-names></name><name><surname>Myers</surname><given-names>C. T.</given-names></name><name><surname>Anyane-Yeboa</surname><given-names>K.</given-names></name><name><surname>Cogn&#x000e9;</surname><given-names>B.</given-names></name><name><surname>Bialer</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Germline <italic>de novo</italic> mutations in GNB1 cause severe neurodevelopmental disability, hypotonia, and seizures</article-title>. <source>Am. J. Hum. Genet.</source>
<volume>98</volume>, <fpage>1001</fpage>&#x02013;<lpage>1010</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2016.03.011</pub-id>
<pub-id pub-id-type="pmid">27108799</pub-id>
</mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pierce</surname><given-names>K. L.</given-names></name><name><surname>Premont</surname><given-names>R. T.</given-names></name><name><surname>Lefkowitz</surname><given-names>R. J.</given-names></name></person-group> (<year>2002</year>). <article-title>Seven-transmembrane receptors</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source>
<volume>3</volume>, <fpage>639</fpage>&#x02013;<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1038/nrm908</pub-id>
<pub-id pub-id-type="pmid">12209124</pub-id>
</mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pires</surname><given-names>D. E.</given-names></name><name><surname>Ascher</surname><given-names>D. B.</given-names></name><name><surname>Blundell</surname><given-names>T. L.</given-names></name></person-group> (<year>2014</year>). <article-title>mCSM: predicting the effects of mutations in proteins using graph-based signatures</article-title>. <source>Bioinformatics</source>
<volume>30</volume>, <fpage>335</fpage>&#x02013;<lpage>342</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btt691</pub-id>
<pub-id pub-id-type="pmid">24281696</pub-id>
</mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reddy</surname><given-names>H. P.</given-names></name><name><surname>Yakubovich</surname><given-names>D.</given-names></name><name><surname>Keren-Raifman</surname><given-names>T.</given-names></name><name><surname>Tabak</surname><given-names>G.</given-names></name><name><surname>Tsemakhovich</surname><given-names>V. A.</given-names></name><name><surname>Pedersen</surname><given-names>M. H.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Encephalopathy-causing mutations in G&#x003b2;<sub>1</sub> (<italic>GNB1</italic>) alter regulation of neuronal GIRK channels</article-title>. <source>iScience</source>
<volume>24</volume>, <fpage>103018</fpage>. <pub-id pub-id-type="doi">10.1016/j.isci.2021.103018</pub-id>
<pub-id pub-id-type="pmid">34522861</pub-id>
</mixed-citation></ref><ref id="B38"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Revah-Politi</surname><given-names>A.</given-names></name><name><surname>Sands</surname><given-names>T. T.</given-names></name><name><surname>Colombo</surname><given-names>S.</given-names></name><name><surname>Goldstein</surname><given-names>D. B.</given-names></name><name><surname>Anyane-Yeboa</surname><given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>GNB1 Encephalopathy. GeneReviews&#x000ae;</article-title>. Editors <person-group person-group-type="editor"><name><surname>Adam</surname><given-names>M. P.</given-names></name><name><surname>Feldman</surname><given-names>J.</given-names></name><name><surname>Mirzaa</surname><given-names>G. M.</given-names></name><name><surname>Pagon</surname><given-names>R. A.</given-names></name><name><surname>Wallace</surname><given-names>S. E.</given-names></name><name><surname>Amemiya</surname><given-names>A.</given-names></name></person-group>
<publisher-loc>Seattle, WA</publisher-loc>: <publisher-name>University of Washington, Seattle</publisher-name>. <fpage>1993</fpage>&#x02013;<lpage>2025</lpage>.</mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rishal</surname><given-names>I.</given-names></name><name><surname>Keren-Raifman</surname><given-names>T.</given-names></name><name><surname>Yakubovich</surname><given-names>D.</given-names></name><name><surname>Ivanina</surname><given-names>T.</given-names></name><name><surname>Dessauer</surname><given-names>C. W.</given-names></name><name><surname>Slepak</surname><given-names>V. Z.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Na+ promotes the dissociation between Galpha GDP and Gbeta gamma, activating G protein-gated K+ channels</article-title>. <source>J. Biol. Chem.</source>
<volume>278</volume>, <fpage>3840</fpage>&#x02013;<lpage>3845</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.C200605200</pub-id>
<pub-id pub-id-type="pmid">12488455</pub-id>
</mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rishal</surname><given-names>I.</given-names></name><name><surname>Porozov</surname><given-names>Y.</given-names></name><name><surname>Yakubovich</surname><given-names>D.</given-names></name><name><surname>Varon</surname><given-names>D.</given-names></name><name><surname>Dascal</surname><given-names>N.</given-names></name></person-group> (<year>2005</year>). <article-title>Gbetagamma-dependent and Gbetagamma-independent basal activity of G protein-activated K+ channels</article-title>. <source>J. Biol. Chem.</source>
<volume>280</volume>, <fpage>16685</fpage>&#x02013;<lpage>16694</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M412196200</pub-id>
<pub-id pub-id-type="pmid">15728579</pub-id>
</mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rubinstein</surname><given-names>M.</given-names></name><name><surname>Peleg</surname><given-names>S.</given-names></name><name><surname>Berlin</surname><given-names>S.</given-names></name><name><surname>Brass</surname><given-names>D.</given-names></name><name><surname>Keren-Raifman</surname><given-names>T.</given-names></name><name><surname>Dessauer</surname><given-names>C. W.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Divergent regulation of GIRK1 and GIRK2 subunits of the neuronal G protein gated K+ channel by GalphaiGDP and Gbetagamma</article-title>. <source>J. Physiol.</source>
<volume>587</volume>, <fpage>3473</fpage>&#x02013;<lpage>3491</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2009.173229</pub-id>
<pub-id pub-id-type="pmid">19470775</pub-id>
</mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schultz-Rogers</surname><given-names>L.</given-names></name><name><surname>Masuho</surname><given-names>I.</given-names></name><name><surname>Pinto</surname><given-names>E. V. F.</given-names></name><name><surname>Schmitz</surname><given-names>C. T.</given-names></name><name><surname>Schwab</surname><given-names>T. L.</given-names></name><name><surname>Clark</surname><given-names>K. J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Haploinsufficiency as a disease mechanism in GNB1-associated neurodevelopmental disorder</article-title>
<volume>8</volume>, <fpage>e1477</fpage>
<pub-id pub-id-type="doi">10.1002/mgg3.1477</pub-id>
</mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shalomov</surname><given-names>B.</given-names></name><name><surname>Friesacher</surname><given-names>T.</given-names></name><name><surname>Yakubovich</surname><given-names>D.</given-names></name><name><surname>Combista</surname><given-names>J. C.</given-names></name><name><surname>Reddy</surname><given-names>H. P.</given-names></name><name><surname>Dabbah</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Ethosuximide: subunit- and G&#x003b2;&#x003b3;-dependent blocker and reporter of allosteric changes in GIRK channels</article-title>. <source>Br. J. Pharmacol.</source>
<volume>182</volume>, <fpage>1704</fpage>&#x02013;<lpage>1718</lpage>.<pub-id pub-id-type="pmid">39814556</pub-id>
</mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singer-Lahat</surname><given-names>D.</given-names></name><name><surname>Dascal</surname><given-names>N.</given-names></name><name><surname>Mittelman</surname><given-names>L.</given-names></name><name><surname>Peleg</surname><given-names>S.</given-names></name><name><surname>Lotan</surname><given-names>I.</given-names></name></person-group> (<year>2000</year>). <article-title>Imaging plasma membrane proteins in large membrane patches of Xenopus oocytes</article-title>. <source>Pflugers Arch.</source>
<volume>440</volume>, <fpage>627</fpage>&#x02013;<lpage>633</lpage>. <pub-id pub-id-type="doi">10.1007/s004240000341</pub-id>
<pub-id pub-id-type="pmid">10958347</pub-id>
</mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tabak</surname><given-names>G.</given-names></name><name><surname>Keren-Raifman</surname><given-names>T.</given-names></name><name><surname>Kahanovitch</surname><given-names>U.</given-names></name><name><surname>Dascal</surname><given-names>N.</given-names></name></person-group> (<year>2019</year>). <article-title>Mutual action by G&#x003b3; and G&#x003b2; for optimal activation of GIRK channels in a channel subunit-specific manner</article-title>. <source>Sci. Rep.</source>
<volume>9</volume>, <fpage>508</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-36833-y</pub-id>
<pub-id pub-id-type="pmid">30679535</pub-id>
</mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tesmer</surname><given-names>J. J.</given-names></name><name><surname>Tesmer</surname><given-names>V. M.</given-names></name><name><surname>Lodowski</surname><given-names>D. T.</given-names></name><name><surname>Steinhagen</surname><given-names>H.</given-names></name><name><surname>Huber</surname><given-names>J.</given-names></name></person-group> (<year>2010</year>). <article-title>Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol</article-title>. <source>J. Med. Chem.</source>
<volume>53</volume>, <fpage>1867</fpage>&#x02013;<lpage>1870</lpage>. <pub-id pub-id-type="doi">10.1021/jm9017515</pub-id>
<pub-id pub-id-type="pmid">20128603</pub-id>
</mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thal</surname><given-names>D. M.</given-names></name><name><surname>Yeow</surname><given-names>R. Y.</given-names></name><name><surname>Schoenau</surname><given-names>C.</given-names></name><name><surname>Huber</surname><given-names>J.</given-names></name><name><surname>Tesmer</surname><given-names>J. J. G.</given-names></name></person-group> (<year>2011</year>). <article-title>Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors</article-title>. <source>Mol. Pharmacol.</source>
<volume>80</volume>, <fpage>294</fpage>&#x02013;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1124/mol.111.071522</pub-id>
<pub-id pub-id-type="pmid">21596927</pub-id>
</mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Touhara</surname><given-names>K. K.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>MacKinnon</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>The GIRK1 subunit potentiates G protein activation of cardiac GIRK1/4 hetero-tetramers</article-title>. <source>Elife</source>
<volume>5</volume>, <fpage>e15750</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.15750</pub-id>
<pub-id pub-id-type="pmid">27074664</pub-id>
</mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsuji</surname><given-names>M.</given-names></name><name><surname>Ikeda</surname><given-names>A.</given-names></name><name><surname>Tsuyusaki</surname><given-names>Y.</given-names></name><name><surname>Iai</surname><given-names>M.</given-names></name><name><surname>Kurosawa</surname><given-names>K.</given-names></name><name><surname>Kosaki</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Atypical clinical course in two patients with GNB1 variants who developed acute encephalopathy</article-title>. <source>Brain Dev.</source>
<volume>45</volume>, <fpage>462</fpage>&#x02013;<lpage>466</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2023.06.005</pub-id>
<pub-id pub-id-type="pmid">37453880</pub-id>
</mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wall</surname><given-names>M. A.</given-names></name><name><surname>Coleman</surname><given-names>D. E.</given-names></name><name><surname>Lee</surname><given-names>E.</given-names></name><name><surname>I&#x000f1;iguez-Lluhi</surname><given-names>J. A.</given-names></name><name><surname>Posner</surname><given-names>B. A.</given-names></name><name><surname>Gilman</surname><given-names>A. G.</given-names></name><etal/></person-group> (<year>1995</year>). <article-title>The structure of the G protein heterotrimer Gi alpha 1 beta 1 gamma 2</article-title>. <source>Cell</source>
<volume>83</volume>, <fpage>1047</fpage>&#x02013;<lpage>1058</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(95)90220-1</pub-id>
<pub-id pub-id-type="pmid">8521505</pub-id>
</mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Touhara</surname><given-names>K. K.</given-names></name><name><surname>Weir</surname><given-names>K.</given-names></name><name><surname>Bean</surname><given-names>B. P.</given-names></name><name><surname>MacKinnon</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>Cooperative regulation by G proteins and Na(+) of neuronal GIRK2 K(+) channels</article-title>. <source>Elife</source>
<volume>5</volume>, <fpage>e15751</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.15751</pub-id>
<pub-id pub-id-type="pmid">27074662</pub-id>
</mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whorton</surname><given-names>M. R.</given-names></name><name><surname>MacKinnon</surname><given-names>R.</given-names></name></person-group> (<year>2013</year>). <article-title>X-ray structure of the mammalian GIRK2-&#x003b2;&#x003b3; G-protein complex</article-title>. <source>Nature</source>
<volume>498</volume>, <fpage>190</fpage>&#x02013;<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1038/nature12241</pub-id>
<pub-id pub-id-type="pmid">23739333</pub-id>
</mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xue</surname><given-names>L. C.</given-names></name><name><surname>Rodrigues</surname><given-names>J. P.</given-names></name><name><surname>Kastritis</surname><given-names>P. L.</given-names></name><name><surname>Bonvin</surname><given-names>A. M.</given-names></name><name><surname>Vangone</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>PRODIGY: a web server for predicting the binding affinity of protein-protein complexes</article-title>. <source>Bioinformatics</source>
<volume>32</volume>, <fpage>3676</fpage>&#x02013;<lpage>3678</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btw514</pub-id>
<pub-id pub-id-type="pmid">27503228</pub-id>
</mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yakubovich</surname><given-names>D.</given-names></name><name><surname>Berlin</surname><given-names>S.</given-names></name><name><surname>Kahanovitch</surname><given-names>U.</given-names></name><name><surname>Rubinstein</surname><given-names>M.</given-names></name><name><surname>Farhy-Tselnicker</surname><given-names>I.</given-names></name><name><surname>Styr</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>A quantitative model of the GIRK1/2 channel reveals that its basal and evoked activities are controlled by unequal stoichiometry of G&#x003b1; and G&#x003b2;&#x003b3;</article-title>. <source>PLoS Comput. Biol.</source>
<volume>11</volume>, <fpage>e1004598</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pcbi.1004598</pub-id>
<pub-id pub-id-type="pmid">26544551</pub-id>
</mixed-citation></ref></ref-list></back></article>